Clinical trials
NKTCL clinical trials
Below are recruiting nktcl clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06559553RecruitingPhase 1/Phase 2
Selinexor, pegaspargase, and dexamethasone for NK/T-cell lymphoma
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Zhengzhou, HenanAges 18–70 - NCT07678229RecruitingPhase 3
Immunotherapy vs Chemotherapy for Advanced NK/T-cell Lymphoma
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07380984RecruitingPhase 2
Immunotherapy and radiation for early-stage nasal-type lymphoma
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
ShanghaiAges 18 years+ - NCT06966154RecruitingPhase 1/Phase 2
Tislelizumab with golidocitinib and selinexor for NK/T-cell lymphoma
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
Shanghai, ShangaiAges 18 years+ - NCT07525466RecruitingPhase 1/Phase 2
New drug combination for NK/T-cell lymphoma with immune complications
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
BeijingAges 18 years+
Hear when a new NKTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nktcl?
- Yes. Clin2 currently lists 5 recruiting nktcl studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nktcl trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nktcl trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.